August 17–21, 2025, Washington, DC, USA - Visit us at Booth 2230.
Read More
Email:
Phone:
Toggle navigation
Home
Services
ADC Linkers Development
Chemically Labile Linkers
Acid Cleavable Linkers/Hydrazone Linkers
Disulfide Linkers
Enzymatically Cleavable Linkers
Cathepsin B Cleavable Linkers/Peptide Linkers
Phosphatase Cleavable Linkers
Sulfatase Cleavable Linkers
β-Galactosidase Cleavable Linkers
β-Glucuronidases Cleavable Linkers
Non-cleavable Linkers
Antibody Modification and Conjugation
Bispecific Antibody Conjugation
Carbohydrate Conjugation
Click Chemistry Conjugation
Cysteine Conjugation
Enzymatic Conjugation
Lysine Conjugation
Non-natural Amino Acids Conjugation
Site-Specific Conjugation
Thio-engineered Antibody
Tyrosine Conjugation
ADC Analysis and Characterization
ADC
In Vitro
Analysis
ADC
In Vivo
Analysis
ADC ADME Characterization
ADC DMPK Analysis
Bioanalytics
Bioassays
Drug Distribution Analysis
Drug-to-Antibody Ratio Analysis
Stability Analysis Services
ADC Linker and Cytotoxin Conjugations
Calicheamicin-based Linker and Cytotoxin Conjugation
Deruxtecan-based Linker and Cytotoxin Conjugation
MMAE/MMAF-based Linker and Cytotoxin Conjugation
PBD-based Linker and Cytotoxin Conjugation
SN-38-based Linker and Cytotoxin Conjugation
ADC Payloads Development
Biological Payloads
Chemical Payloads
Protein Toxins
ADC Manufacture
ADC cGMP Manufacture
ADC Fill/Finish
ADC Formulation Development
ADC Purification
ADC Development for Targets
ADC Development for AXL Targets
ADC Development for BCMA Targets
ADC Development for CD19 Targets
ADC Development for CD22 Targets
ADC Development for CD30 Targets
ADC Development for CD33 Targets
ADC Development for CD79b Targets
ADC Development for c-MET Targets
ADC Development for EGFR Targets
ADC Development for FOLR1 Targets
ADC Development for HER2 Targets
ADC Development for Nectin-4 Targets
ADC Development for ROR1 Targets
ADC Development for TF Targets
ADC Development for TROP-2 Targets
ADC Development Platform
Antibody Fragment-Drug Conjugates (FDCs)
Bispecific Antibody-Drug Conjugates (BsADCs)
Degrader-Antibody Conjugates (DACs)
Dual-Payload Antibody–Drug Conjugates
Nanobody-Drug Conjugates (NDCs)
Scaffold-Drug Conjugates (SDCs)
Products
ADCs Cytotoxin
Auristatins
Calicheamicins
Camptothecins
Daunorubicins/Doxorubicins
Duocarmycins
Maytansinoids
Piericidins
Pyrrolobenzodiazepines
Traditional Cytotoxic Agents
Others
ADCs Cytotoxin with Linkers
ADCs Linker
Cleavable Linkers
Non-cleavable Linkers
Antibody-Drug Conjugates (ADCs)
Resource
Frequently Asked Questions
News
Scientific Corner
Support Documents
Company
Contact Us
About Us
Careers
Inquiry
Support Documents
Home
Resource
Support Documents
Support Documents
Brochures
ADCs Cytotoxin − Auristatins
ADCs Cytotoxin − Calicheamicins
ADCs Cytotoxin − Camptothecins
ADCs Cytotoxin − Doxorubicins
ADCs Cytotoxin − Duocarmycins
ADCs Cytotoxin − Maytansinoids
ADCs Cytotoxin − Pyrrolobenzodiazepines
Flyer
ADC Analysis and Characterization
ADC Conjugation Services
ADC Cytotoxins Development
ADC Development for Targets
ADC Manufacture Services
Linkers Development Services
Posters
The R&D Barriers of Antibody-drug Conjugates
Inquiry Basket
Loading ......
Delete selected
Go to checkout
